New weekly injection shows promise for weight loss in early trial

NCT ID NCT07184632

Ongoing Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called NNC0662-0419, given as a weekly shot, to see if it helps people with overweight or obesity lose weight safely. About 224 adults aged 18-65 with a BMI of 27 or higher will receive either the drug or a placebo. The main goals are to check for side effects and measure weight change over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0662-0419
What this could lead to: If successful, this could lead to a new once-weekly injection for weight management in people with overweight or obesity.
What could go wrong: This is an early Phase 2 trial with only 224 participants, so results may not apply to everyone. The drug is still experimental and may have side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Celerion, Lincoln

Lincoln, Nebraska, 68502, United States
Celerion, Phoenix

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.